The GAA gene in humans codes for the enzyme lysosomal alpha-glucosidase. It's also known as glucosidase-1, 4-glucosidase, and acid maltase. Glycogen storage disease type II and Pompe disease are caused by abnormalities in this gene. This gene produces acid alpha-glucosidase, which is required for the conversion of glycogen to glucose in lysosomes. Different types of acid alpha-glucosidase can be obtained through proteolytic processing. This gene has three transcript variants that all code for the same protein. Glycogen storage disease and Pompe disease are treated with lysosomal alpha-glucosidase.
The rising prevalence of disorders such as glycogen storage disease and Pompe disease, as well as the growing population, are driving the market for lysosomal alpha glucosidase.
Lysosomal Alpha Glucosidase Market- Regional Analysis
The lysosomal alpha glucosidase market has been divided into North America, Latin America, Europe, the Middle East, Asia Pacific, and Africa based on geography. Because of the greater rate of incidence in this region, Europe is likely to be the leading market during the projection period. According to a BMJ Paediatrics Open research published in February 2018, the incidence of infantile Pompe illness in the Maroon population of France is around 50 times higher than anywhere else in the globe.
Read More: https://bit.ly/3Fl8PNG
